CoronaryAtlas logo
CoronaryAtlas
Uric acid
Pathway / Plaque inflammation

Uric acid

metabolite

Uric acid accumulates during oxidative injury and endothelial dysfunction in acute MI, serving as a biomarker of inflammatory burden and CAD severity.

Pathway placement
Cascade stepPlaque inflammation
Confidencemedium
RationaleOxidative stress and inflammation marker; endothelial dysfunction driver; elevated in ACS; links hyperuricemia to MI and coronary pathology.
Also acts inEndothelial activation/erosion, Lipid entry/oxidation
Druggability
Not assessed (no mapped human gene target).

Type I vs Type II discrimination

ScoresIndeterminate
R — rupture / Type-I
—
C — confounder / Type-II
33
A — assay feasibility
84
E — evidence strength
39
T1DI (composite)
13
Specificity differential (R−C)-18.3
Confounder panel (Type-II drivers)
1sepsis / systemic inflammationn/a
2anemia / acute blood lossn/a
3hypovolemia / dehydrationn/a
4tachyarrhythmiamag 1
5hypoxemia / respiratory failuren/a
6hypertensive emergencyn/a
7high-demand / peri-operative stressn/a
Coverage: 1/7 confounders with evidence
Tier: deep-scored (abstract-extracted) · 1 supporting references. See the discrimination table for all markers.

Assay & specimen

Validated clinical assay
Specimen
Serum, plasma or urine
Collection tube
Serum separator (gold/red-top, SST) · Lithium heparin (green-top) · Sterile urine container
Method / principle
Enzymatic (uricase)
Reagent / substrate
Uricase → allantoin + H2O2; peroxidase Trinder, read 550 nm
Platform
Automated analyzer
Turnaround · availability
Routine · Universal

Literature evidence(8)